These findings support the GPC3-targeted immunotoxins in HCC treatment, particularly in tumors resistant to conventional therapies and suggest that this approach may be adaptable for other diseases requiring targeted cell elimination [143]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.